Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

para-toluenesulfonamide

A low-molecular-weight organic compound with potential antineoplastic activity. Upon intra-tumoral injection, para-toluenesulfonamide increases lysosomal membrane permeabilization (LMP) and the release of cathepsin B. Cytosolic cathepsin B released from lysosomes cleaves and activates proapoptotic B-cell lymphoma 2 (Bcl-2) family member BH3 interacting-domain death agonist (Bid) and poly [ADP-ribose] polymerase 1 (PARP-1), which may induce tumor cell death.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:p-toluenesulfonamide
Abbreviation:PTS
Code name:PTS 100
PTS-100
PTS100
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search